JP7541516B2 - ナチュラルキラー(nk)細胞サブセットの増大のための方法ならびに関連する組成物および方法 - Google Patents
ナチュラルキラー(nk)細胞サブセットの増大のための方法ならびに関連する組成物および方法 Download PDFInfo
- Publication number
- JP7541516B2 JP7541516B2 JP2021528350A JP2021528350A JP7541516B2 JP 7541516 B2 JP7541516 B2 JP 7541516B2 JP 2021528350 A JP2021528350 A JP 2021528350A JP 2021528350 A JP2021528350 A JP 2021528350A JP 7541516 B2 JP7541516 B2 JP 7541516B2
- Authority
- JP
- Japan
- Prior art keywords
- cells
- neg
- enriched
- negative
- population
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/804—Blood cells [leukemia, lymphoma]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/892—Reproductive system [uterus, ovaries, cervix, testes]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Urology & Nephrology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Developmental Biology & Embryology (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024135820A JP2024161503A (ja) | 2018-11-21 | 2024-08-16 | ナチュラルキラー(nk)細胞サブセットの増大のための方法ならびに関連する組成物および方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862770686P | 2018-11-21 | 2018-11-21 | |
| US62/770,686 | 2018-11-21 | ||
| PCT/US2019/062695 WO2020107002A2 (en) | 2018-11-21 | 2019-11-21 | Methods for expansion of natural killer (nk) cell subset and related compositions and methods |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024135820A Division JP2024161503A (ja) | 2018-11-21 | 2024-08-16 | ナチュラルキラー(nk)細胞サブセットの増大のための方法ならびに関連する組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022511735A JP2022511735A (ja) | 2022-02-01 |
| JP2022511735A5 JP2022511735A5 (cg-RX-API-DMAC7.html) | 2022-11-30 |
| JP7541516B2 true JP7541516B2 (ja) | 2024-08-28 |
Family
ID=68841253
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021528350A Active JP7541516B2 (ja) | 2018-11-21 | 2019-11-21 | ナチュラルキラー(nk)細胞サブセットの増大のための方法ならびに関連する組成物および方法 |
| JP2024135820A Pending JP2024161503A (ja) | 2018-11-21 | 2024-08-16 | ナチュラルキラー(nk)細胞サブセットの増大のための方法ならびに関連する組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024135820A Pending JP2024161503A (ja) | 2018-11-21 | 2024-08-16 | ナチュラルキラー(nk)細胞サブセットの増大のための方法ならびに関連する組成物および方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US12410402B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3884041A2 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7541516B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20210123289A (cg-RX-API-DMAC7.html) |
| CN (1) | CN113891934A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020107002A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10066207B2 (en) | 2012-04-18 | 2018-09-04 | Board Of Trustees Of Michigan State University | Natural killer cells with enhanced immune response |
| AU2018219895C1 (en) | 2017-02-09 | 2024-10-03 | Indapta Therapeutics, Inc. | Engineered Natural Killer (NK) cells and compositions and methods thereof |
| EP3884041A2 (en) | 2018-11-21 | 2021-09-29 | Indapta Therapeutics, Inc. | Methods for expansion of natural killer (nk) cell subset and related compositions and methods |
| KR20230088306A (ko) * | 2020-04-22 | 2023-06-19 | 인답타 세라뷰틱스 인코포레이티드 | 자연 살해(nk) 세포 조성물 및 이를 생성하는 방법 |
| US20240197783A1 (en) * | 2021-04-21 | 2024-06-20 | Indapta Therapeutics, Inc. | Methods of treatment and dosing of natural killer cell compositions |
| KR20240051112A (ko) | 2021-07-01 | 2024-04-19 | 인답타 세라뷰틱스 인코포레이티드 | 조작된 자연 살해(nk) 세포 및 관련 방법 |
| IL310226A (en) * | 2021-07-18 | 2024-03-01 | Gamida Cell Ltd | Therapeutic nk cell populations |
| CN119643843B (zh) * | 2022-03-15 | 2025-08-12 | 上海君赛生物科技有限公司 | 肿瘤特异性免疫细胞标志物及其用途 |
| US20250375524A1 (en) | 2022-06-30 | 2025-12-11 | Indapta Therapeutics, Inc. | Combination of engineered natural killer (nk) cells and antibody therapy and related methods |
| WO2025213127A1 (en) | 2024-04-05 | 2025-10-09 | Indapta Therapeutics, Inc. | Treatment of autoimmune diseases or conditions with natural killer cells |
| WO2025245399A1 (en) | 2024-05-23 | 2025-11-27 | Indapta Therapeutics, Inc. | Method of treating cancer with natural killer cells |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011529341A (ja) | 2008-07-29 | 2011-12-08 | グリーン・クロス・コーポレイション | ナチュラルキラー細胞の増殖方法 |
| JP2012521215A (ja) | 2009-03-26 | 2012-09-13 | アヴァリス・アクチエボラーグ | Nk細胞の増殖 |
| US20130295044A1 (en) | 2012-04-18 | 2013-11-07 | Board Of Trustees Of Michigan State University | Natural killer cells with enhanced immune response |
| WO2016151741A1 (ja) | 2015-03-23 | 2016-09-29 | 株式会社セレックス | Nk細胞培養容器及びnk細胞培養方法 |
| WO2018148462A1 (en) | 2017-02-09 | 2018-08-16 | Indapta Therapeutics, Inc. | Engineered natural killer (nk) cells and compositions and methods thereof |
| JP2019170176A (ja) | 2018-03-27 | 2019-10-10 | 株式会社ガイアバイオメディシン | ケモカインレセプターと細胞接着分子を発現するcd3陰性細胞の集団、およびその利用 |
Family Cites Families (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4889818A (en) | 1986-08-22 | 1989-12-26 | Cetus Corporation | Purified thermostable enzyme |
| US5716826A (en) | 1988-03-21 | 1998-02-10 | Chiron Viagene, Inc. | Recombinant retroviruses |
| US20020159979A1 (en) | 1994-06-06 | 2002-10-31 | Children's Hospital, Inc. | Adeno-associated virus materials and methods |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US7153510B1 (en) | 1995-05-04 | 2006-12-26 | Yale University | Recombinant vesiculoviruses and their uses |
| FR2735789B1 (fr) | 1995-06-23 | 1997-07-25 | Centre Nat Rech Scient | Adenovirus recombinants, leur utilisation pour preparer des aav, lignee cellulaire complementaire et compositions pharmaceutiques les contenant |
| JPH11514853A (ja) | 1995-09-08 | 1999-12-21 | ジエンザイム コーポレイション | 遺伝子治療のための改良されたaavベクター |
| US7001765B2 (en) | 1996-03-06 | 2006-02-21 | Medigene Ag | Adeno-associated virus vector for boosting immunogenicity of cells |
| CA2300957A1 (en) | 1997-08-15 | 1999-02-25 | Rubicon Laboratory, Inc. | Retrovirus and viral vectors |
| JP2001517454A (ja) | 1997-09-19 | 2001-10-09 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 組換えアデノ随伴ウイルスの産生に有用な方法および細胞株 |
| GB9801930D0 (en) | 1998-01-29 | 1998-03-25 | Univ London | Mutant herpes simplex viruses and uses thereof |
| WO1999043208A1 (en) | 1998-02-27 | 1999-09-02 | The General Hospital Corporation | The helios gene |
| US20040063094A1 (en) | 1998-05-20 | 2004-04-01 | Biovex Limited | Mutant herpes simplex viruses and uses thereof |
| US6436392B1 (en) | 1998-05-20 | 2002-08-20 | University Of Iowa Research Foundation | Adeno-associated virus vectors |
| EP1135468B1 (en) | 1998-11-10 | 2010-01-06 | University Of North Carolina At Chapel Hill | Virus vectors and methods of making and administering the same |
| GB9904582D0 (en) | 1999-02-26 | 1999-04-21 | Nycomed Imaging As | Process |
| US6428968B1 (en) | 1999-03-15 | 2002-08-06 | The Trustees Of The University Of Pennsylvania | Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject |
| US6168991B1 (en) | 1999-06-25 | 2001-01-02 | Lucent Technologies Inc. | DRAM capacitor including Cu plug and Ta barrier and method of forming |
| DE19933288A1 (de) | 1999-07-15 | 2001-01-18 | Medigene Ag | Strukturprotein von Adeno-assoziiertem Virus mit veränderter Antigenität, seine Herstellung und Verwendung |
| US7241447B1 (en) | 1999-10-07 | 2007-07-10 | University Of Iowa Research Foundation | Adeno-associated virus vectors and uses thereof |
| WO2001045737A2 (en) | 1999-12-22 | 2001-06-28 | Onyx Pharmaceuticals, Inc. | Herpes simplex virus-1 glycoprotein c mutants for treating unwanted hyperproliferative cell growth |
| JP4810042B2 (ja) | 2000-01-21 | 2011-11-09 | バイオヴェックス リミテッド | ヘルペスウイルス株 |
| US7306902B2 (en) | 2002-06-28 | 2007-12-11 | Oncolyties Biotech Inc. | Oncolytic viruses as phenotyping agents for neoplasms |
| US6653103B2 (en) | 2001-03-30 | 2003-11-25 | Wisconsin Alumni Research Foundation | Inhibition of nucleocytoplasmic transport by vesicular stomatitis virus M protein-like polypeptides |
| NZ527687A (en) | 2001-05-11 | 2005-10-28 | Wellstat Biolog Corp Formerly | Preferential binding of an oncolytic virus such as Newcastle Disease Virus (NDV) to leukocytes compared with erythrocytes used as a therapy for cancer |
| CA2452517A1 (en) | 2001-07-11 | 2003-01-23 | University Of Miami | Recombinant vsv for the treatment of tumor cells |
| WO2003082200A2 (en) | 2002-03-27 | 2003-10-09 | Baylor College Of Medicine | Potent oncolytic herpes simplex virus for cancer therapy |
| US20030225260A1 (en) | 2002-04-30 | 2003-12-04 | Snyder Richard O. | Production of recombinant AAV virions |
| US20050220818A1 (en) | 2002-06-21 | 2005-10-06 | Wellstat Biologics Corporation | Administration of therapeutic viruses |
| CA2498297A1 (en) | 2002-09-09 | 2004-03-18 | University Of Tennessee Research Foundation | Recombinatant mutants of rhabdovirus and methods of use thereof |
| ATE539162T1 (de) | 2003-03-27 | 2012-01-15 | Ottawa Hospital Res Inst | Mutierte viren der vesikulären stomatitis und deren verwendung |
| US7731974B2 (en) | 2003-03-27 | 2010-06-08 | Ottawa Hospital Research Institute | Mutant vesicular stomatitis viruses and uses thereof |
| MXPA05013879A (es) | 2003-06-18 | 2006-06-27 | Genelux Corp | Virus de la vaccinia recombinantes modificados y otros microorganismos, y usos de los mismos. |
| EP1668143B1 (en) | 2003-09-30 | 2013-03-20 | The Trustees of The University of Pennsylvania | Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor |
| GB0326798D0 (en) | 2003-11-17 | 2003-12-24 | Crusade Lab Ltd | Methods for generating mutant virus |
| JP2007511216A (ja) | 2003-11-17 | 2007-05-10 | クルセイド ラボラトリーズ リミテッド | 変異ウイルス |
| US7897146B2 (en) | 2003-11-17 | 2011-03-01 | Crusade Laboratories Limited | Treatment using herpes simplex virus |
| WO2005116224A2 (en) | 2004-05-18 | 2005-12-08 | Children's Memorial Hospital | Tetracycline-regulated adeno-associated viral (aav) vectors for gene delivery to the nervous system |
| US7427396B2 (en) | 2004-06-03 | 2008-09-23 | Genzyme Corporation | AAV vectors for gene delivery to the lung |
| WO2006002394A2 (en) | 2004-06-24 | 2006-01-05 | New York University | Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response |
| ES2678094T3 (es) | 2004-07-10 | 2018-08-08 | Fox Chase Cancer Center | Líneas de células asesinas naturales genéticamente modificadas |
| EP1819823A2 (en) | 2004-12-01 | 2007-08-22 | Bayer Schering Pharma Aktiengesellschaft | Generation of replication competent viruses for therapeutic use |
| EP2963118B1 (en) | 2005-06-01 | 2017-08-09 | California Institute of Technology | Method of targeted gene delivery using viral vectors |
| US8986672B2 (en) | 2005-06-23 | 2015-03-24 | The University Of Houston | Use of mutant Herpes Simplex Virus-2 for cancer therapy |
| US7943374B2 (en) | 2005-08-21 | 2011-05-17 | Markus Hildinger | Super-size adeno-associated viral vector harboring a recombinant genome larger than 5.7 kb |
| GB0522476D0 (en) | 2005-11-03 | 2005-12-14 | Biovex Ltd | Oncolytic herpes virus vectors |
| EP2415783B1 (en) | 2006-10-16 | 2016-12-14 | Genelux Corporation | Modified vaccinia virus strains for use in a diagnostic and therapeutic method |
| WO2008140621A2 (en) | 2006-12-21 | 2008-11-20 | Mount Sinai School Of Medicine Of New York University | Transgenic oncolytic viruses and uses thereof |
| JP5442452B2 (ja) | 2007-02-16 | 2014-03-12 | ウイルツ・バイオロジクス・リミテッド | 単純ヘルペスウイルスおよびウイルス複製法 |
| US8110379B2 (en) | 2007-04-26 | 2012-02-07 | Sangamo Biosciences, Inc. | Targeted integration into the PPP1R12C locus |
| WO2008156655A2 (en) | 2007-06-15 | 2008-12-24 | Genelux Corporation | Vaccinia virus vectors encoding a sodium-dependent transporter protein for imaging and/or treatment of tumors |
| JP2010533718A (ja) | 2007-07-18 | 2010-10-28 | ジェネラックス・コーポレイション | 腫瘍溶解性ウイルス治療に付随する副作用の処置もしくは改善用医薬の製造における化学治療剤の使用 |
| WO2009041113A1 (ja) | 2007-09-28 | 2009-04-02 | Olympus Corporation | Fc受容体遺伝子導入NK細胞、その作製方法、及びこれを用いた抗体依存性細胞障害のアッセイ方法 |
| WO2009054996A2 (en) | 2007-10-25 | 2009-04-30 | Genelux Corporation | Systems and methods for viral therapy |
| US8313896B2 (en) | 2008-04-04 | 2012-11-20 | The General Hospital Corporation | Oncolytic herpes simplex virus immunotherapy in the treatment of brain cancer |
| WO2009139921A2 (en) | 2008-05-16 | 2009-11-19 | Genelux Corporation | Microorganisms for preventing and treating neoplasms accompanying cellular therapy |
| WO2009148488A2 (en) | 2008-05-29 | 2009-12-10 | The General Hospital Corporation | Use of oncolytic herpes viruses for killing cancer stem cells |
| US8481297B2 (en) | 2009-01-08 | 2013-07-09 | Yale University | Compositions and methods of use of an oncolytic vesicular stomatitis virus |
| WO2012061814A1 (en) | 2010-11-05 | 2012-05-10 | Transgenomic, Inc. | Pcr primers and methods for rapid and specific genotyping |
| US11471486B2 (en) * | 2012-09-04 | 2022-10-18 | Inven2 As | Selective and controlled expansion of educated NK cells |
| ES2769574T3 (es) | 2013-03-15 | 2020-06-26 | Michael C Milone | Reconocimiento de células citotóxicas con receptores quiméricos para inmunoterapia adoptiva |
| US9902973B2 (en) | 2013-04-11 | 2018-02-27 | Caribou Biosciences, Inc. | Methods of modifying a target nucleic acid with an argonaute |
| WO2015103438A2 (en) | 2014-01-02 | 2015-07-09 | Genelux Corporation | Oncolytic virus adjunct therapy with agents that increase virus infectivity |
| US10738278B2 (en) | 2014-07-15 | 2020-08-11 | Juno Therapeutics, Inc. | Engineered cells for adoptive cell therapy |
| US10813952B2 (en) | 2014-11-14 | 2020-10-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | NK cells with an increased antibody-dependent cellular toxicity (ADCC) against tumors |
| AU2016274989A1 (en) | 2015-06-12 | 2017-11-02 | Immunomedics, Inc. | Disease therapy with chimeric antigen receptor (car) constructs and t cells (car-t) or nk cells (car-nk) expressing car constructs |
| JP7033453B2 (ja) | 2015-06-30 | 2022-03-10 | セレクティス | 特異的エンドヌクレアーゼを使用した遺伝子不活化によってnk細胞の機能性を改善する方法 |
| EP3828266B1 (en) | 2015-07-29 | 2022-11-23 | ONK Therapeutics Limited | Modified natural killer cells and natural killer cell lines having increased cytotoxicity |
| EP3349770A1 (en) | 2015-09-14 | 2018-07-25 | Regents of the University of Minnesota | Nk cells exhibiting an adaptive phenotype and methods for preparing and for using |
| CN122146606A (zh) | 2015-11-04 | 2026-06-05 | 菲特治疗公司 | 用于诱导造血细胞分化的方法和组合物 |
| US12642852B1 (en) | 2015-11-04 | 2026-06-02 | Fate Therapeutics, Inc. | Genomic engineering of pluripotent cells |
| AU2017210031C1 (en) | 2016-01-20 | 2020-11-26 | Fate Therapeutics, Inc. | Compositions and methods for immune cell modulation in adoptive immunotherapies |
| JP7653759B2 (ja) | 2016-01-20 | 2025-03-31 | フェイト セラピューティクス,インコーポレイテッド | 養子免疫療法における免疫細胞調節のための組成物および方法 |
| EP3487991B1 (en) * | 2016-07-25 | 2022-09-07 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Methods of producing modified natural killer cells and methods of use |
| EP3539552A1 (en) | 2018-03-16 | 2019-09-18 | Deutsches Rheuma-Forschungszentrum Berlin | Activation and expansion of nkg2c+ nk cells |
| CN112839666A (zh) | 2018-05-14 | 2021-05-25 | 因达普塔治疗公司 | 具有增强的抗体导向免疫应答的人自然杀伤细胞亚群 |
| EP3884041A2 (en) | 2018-11-21 | 2021-09-29 | Indapta Therapeutics, Inc. | Methods for expansion of natural killer (nk) cell subset and related compositions and methods |
-
2019
- 2019-11-21 EP EP19817911.1A patent/EP3884041A2/en active Pending
- 2019-11-21 KR KR1020217018988A patent/KR20210123289A/ko active Pending
- 2019-11-21 US US17/295,849 patent/US12410402B2/en active Active
- 2019-11-21 JP JP2021528350A patent/JP7541516B2/ja active Active
- 2019-11-21 WO PCT/US2019/062695 patent/WO2020107002A2/en not_active Ceased
- 2019-11-21 CN CN201980089592.XA patent/CN113891934A/zh active Pending
-
2024
- 2024-08-16 JP JP2024135820A patent/JP2024161503A/ja active Pending
-
2025
- 2025-08-14 US US19/300,464 patent/US20260043006A1/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011529341A (ja) | 2008-07-29 | 2011-12-08 | グリーン・クロス・コーポレイション | ナチュラルキラー細胞の増殖方法 |
| JP2012521215A (ja) | 2009-03-26 | 2012-09-13 | アヴァリス・アクチエボラーグ | Nk細胞の増殖 |
| US20130295044A1 (en) | 2012-04-18 | 2013-11-07 | Board Of Trustees Of Michigan State University | Natural killer cells with enhanced immune response |
| WO2016151741A1 (ja) | 2015-03-23 | 2016-09-29 | 株式会社セレックス | Nk細胞培養容器及びnk細胞培養方法 |
| WO2018148462A1 (en) | 2017-02-09 | 2018-08-16 | Indapta Therapeutics, Inc. | Engineered natural killer (nk) cells and compositions and methods thereof |
| JP2019170176A (ja) | 2018-03-27 | 2019-10-10 | 株式会社ガイアバイオメディシン | ケモカインレセプターと細胞接着分子を発現するcd3陰性細胞の集団、およびその利用 |
Non-Patent Citations (5)
| Title |
|---|
| A. B. Bigley et al.,Clinical and Experimental Immunology,2016年,Vol. 185,pp.239-251 |
| A. B. Bigley et al.,Clinical and Experimental Immunology,2018年09月,Vol. 193,pp. 265-274 |
| Hiroyuki Fujisaki et al.,Cancer Res,2009年,Vol. 69, No. 9,pp.4010-4017 |
| Jaewon Lee et al.,Immunity,2015年,Vol. 42,pp. 431-442 |
| Tianxiang Zhang et al.,The Journal of Immunology,2013年,Vol. 190,pp. 1402-1406 |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20210123289A (ko) | 2021-10-13 |
| US12410402B2 (en) | 2025-09-09 |
| CN113891934A (zh) | 2022-01-04 |
| WO2020107002A2 (en) | 2020-05-28 |
| JP2022511735A (ja) | 2022-02-01 |
| US20220008466A1 (en) | 2022-01-13 |
| WO2020107002A3 (en) | 2020-07-23 |
| JP2024161503A (ja) | 2024-11-19 |
| US20260043006A1 (en) | 2026-02-12 |
| EP3884041A2 (en) | 2021-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20260043006A1 (en) | Methods for expansion of natural killer (nk) cell subset and related compositions and methods | |
| EP3793573B1 (en) | Subsets of human natural killer cells with enhanced antibody-directed immune responses | |
| US20230190801A1 (en) | Natural killer (nk) cell compositions and methods for generating same | |
| US20240294874A1 (en) | Engineered natural killer (nk) cells and compositions and methods thereof | |
| US20240316102A1 (en) | Engineered natural killer (nk) cells and related methods | |
| US20240197783A1 (en) | Methods of treatment and dosing of natural killer cell compositions | |
| US12163153B2 (en) | Methods of manufacturing allogeneic CAR T cells | |
| JP2024526837A (ja) | 治療用nk細胞集団 | |
| CN117915929A (zh) | 工程化自然杀伤(nk)细胞和相关方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221121 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20221121 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20230807 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231113 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240208 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240510 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240723 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240816 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7541516 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |